Textbook of Autism Spectrum Disorders, Second Edition
- List Price
- APA Members
- APA Resident-Fellow Members
More than 40 years after the official recognition of infantile autism in DSM-III, numerous questions remain about autism spectrum disorder (ASD)—its possible causes, assessment, and most effective treatments.
This second edition of the Textbook of Autism Spectrum Disorders features contributions from dozens of experts as it reviews the latest research on these topics and more.
As ambitious in scope and exhaustive as the preceding edition, this guide is organized by sections that tackle:
- Assessment and evaluation, including recognizing the lower- and higher-order repetitive behaviors characteristic of ASD, as well as its comorbidities. Chapters also discuss the roles that racial and ethnic disparities, gender and sexual identities,and biomarkers and technology—including smart home devices and augmented reality technology—can play in assessment and evaluation.
- The possible causes of autism, from prenatal, perinatal, and parental risk factors to syndromic causes of ASD, updates on genetic testing, and the effect of environmental factors and immune dysregulation.
- Standard and experimental treatments in autism. Chapters analyze the role of pharmacotherapies such as serotonergic antidepressants, atypical antipsychotics, and experimental therapeutics (e.g., oxytocin, vasopressin) as well as the use of cannabis, cannabinoids, and immunomodulatory agents. The book also examines behavioral treatments, interventions in schools, complementary and integrative medicine approaches, stem cell and gene therapies, and more.
- Social policy issues, including the role of patient advocacy groups in treatment development and an examination of autism strengths and the growing emphasis on recognizing neurodiversity.
Unrivaled in its thoroughness, the book includes summary points in each chapter for ease of reference and lists of recommended readings that offer readers the opportunity for further study and exploration. For all those in the ASD continuum of care—psychiatrists, psychologists, neurologists, social workers, speech therapists, educators, and patient families—this is an essential resource.
PART I: Assessment, Evaluation, and Target Symptoms
- PART IA: Assessment and Evaluation
- Chapter 1. Epidemiology
- Chapter 2. Psychiatric Assessment and Treatment
- Chapter 3. Pediatric and Neurological Assessments
- Chapter 4. Gender Dysphoria, Gender Incongruence, and Sexual Identity
- Chapter 5. Racial and Ethnic Disparities in Assessment and Evaluation
- Chapter 6. Digital Biomarkers in Diagnostics and Monitoring
PART IB: Target and Comorbid Symptoms
- Chapter 7. Social Communication
- Chapter 8. Diet and Nutrition
PART II: Causes
- PART IIA: Overview
- Chapter 9. Genetics and Genomics
- Chapter 10. Epigenomics
- Chapter 11. Prenatal, Perinatal, and Parental Risk Factors
- Chapter 12. Animal Models
- Chapter 13. Electrophysiological Studies
- Chapter 14. Environmental Toxicity and Immune Dysregulation
PART IIB: Syndromic Causes
- Chapter 15. Overview of Syndromic Causes of Autism and Commonalities in Neurobiological Pathways
- Chapter 16. Fragile X Syndrome and Associated Disorders
- Chapter 17. Tuberous Sclerosis Complex
- Chapter 18. 16p11.2 and Other Recurrent Copy Number Variants Associated With ASD Susceptibility
- Chapter 19. Rett Syndrome
- Chapter 20. Prader-Willi Syndrome
PART IIC: Imaging and Anatomy
- Chapter 21. Neuroanatomical Findings
- Chapter 22. The Amygdala in ASD
- Chapter 23. Neurobiology of ASD Informed by Structural Imaging Research
- Chapter 24. Positron Emission Tomography
- Chapter 25. Functional Magnetic Resonance Imaging
PART III: Treatments and Interventions
- PART IIIA: Standard Pharmacological Treatments
- Chapter 26. Serotonergic Medication
- Chapter 27. Antipsychotics
- Chapter 28. Treating Hyperactivity in Children With Pervasive Developmental Disorders
PART IIIB: Experimental Therapeutics
- Chapter 29. Complementary and Integrative Approaches
- Chapter 30. Oxytocin
- Chapter 31. Vasopressin
- Chapter 32. N-Acetylcysteine
- Chapter 33. Arbaclofen: From Animal Models to Clinical Trials
- Chapter 34. Cannabis, Cannabinoids, and Immunomodulatory Agents
PART IIIC: Behavioral and Educational Interventions
- Chapter 35. Behavioral Treatments
- Chapter 36. Early Start Denver Model
- Chapter 37. The Developmental, Individual Difference, Relationship-Based Intervention Model: A Comprehensive Parent-Mediated Approach
- Chapter 38. School-Based Interventions
- Chapter 39. Language and Communication: Challenges and Treatments
PART IIID: Future Treatment Developments
- Chapter 40. Transcranial Magnetic Stimulation
- Chapter 41. Stem Cell and Gene Therapy
- Chapter 42. Gene Therapy and Molecular Interventions
PART IV: Consortiums, Employment, and Advocacy
- Chapter 44. Consortiums:
- Developing Precision Medicine Approaches to ASD Conditions
- Autism Biomarkers Consortium for Clinical Trials
- Interactive Autism Network
- Chapter 45. Autism Strengths and Neurodiversity
- Chapter 46. Role of Patient Advocacy Groups in Treatment Development
- Leonard Abbeduto, Ph.D.
Amitha L. Ananth, M.D.
Jocelyne Bachevalier, Ph.D.
Jennifer M. Bain, M.D., Ph.D.
Elizabeth L. Berg, Ph.D.
Sven Bolte, Ph.D.
Jordan Brooks, Pharm.D.
Diane C. Chugani, Ph.D.
John N. Constantino, M.D.
Nycole A. Copping, Ph.D.
Marta del Valle Rubido, M.Pharm.
Marilena M. DeMayo, Ph.D.
Elise Douard, M.Sc.
Sarah Dufek, Ph.D., BCBA-D
Evan E. Eichler, Ph.D.
Peter G. Enticott, Ph.D.
Craig A. Erickson, M.D.
Casara Jean Ferretti, M.S., M.A.
Kyle D. Fink, Ph.D.
Eric Fombonne, M.D.
Paulo Fontoura, M.D., Ph.D.
Nora D.B. Friedman, M.D.
Elizabeth A. Fuller, Ph.D., BCBA
Lawrence K. Fung, M.D., Ph.D.
Raz Gross, M.D., M.P.H.
Christophe Grundschober, Ph.D.
Adam J. Guastella, Ph.D.
Randi J. Hagerman, M.D.
Ester Hamo, B.S.
David R. Hampson, Ph.D.
Antonio Y. Hardan, M.D.
Heather Cody Hazlett, Ph.D.
John P. Hegarty II, Ph.D.
Robert L. Hendren, D.O.
Alison Presmanes Hill, Ph.D.
Tomoya Hirota, M.D.
Eric Hollander, M.D.
Alexander W.M. Hooper, Ph.D.
Sebastien Jacquemont, M.D.
Aron Janssen, M.D.
Anahid Kabasakalian, M.D.
Tatyana Kanzaveli, M.S.
Ori Kapra, B.A.
Connie Kasari, Ph.D.
Walter E. Kaufmann, M.D.
Daniel P. Kennedy, Ph.D.
Bryan H. King, M.D., M.B.A.
Dorit Kliemann, Ph.D.
Alexander Kolevzon, M.D.
Janine M. LaSalle, Ph.D.
J. Kiely Law, M.D., M.P.H.
Grace Olive Lawley, B.A.
Brittany Lawton, M.S.W., M.A.
Kayla Applebaum Levine, M.D.
Paul H. Lipkin, M.D.
Sarah Lippe, Ph.D.
Eva Loth, Ph.D.
Rebecca P.F. MacDonald, Ph.D., BCBA-D
Heather MacFarlane, B.A.
David Mandell, Ph.D.
Veronica Martinez-Cerdeno, Ph.D.
Melissa Maye, Ph.D.
Christopher J. McDougle, M.D.
Emily McFadd, Ph.D., CCC-SLP
James C. McPartland, Ph.D.
Charles E. Mordaunt, Ph.D.
Declan Murphy, M.D., FRCPsych
Vera Nezgovorova, M.D.
Christine Wu Nordahl, Ph.D.
Stefano Pallanti, M.D., Ph.D.
Alan K. Percy, M.D.
Diana Perry-Cruwys, Ph.D., BCBA-D
Isaac N. Pessah, Ph.D.
Pamela Peterson, BCBA
Stela P. Petkova, Ph.D.
Laura A. Potter, B.A.
Dannah Raz, M.D., M.P.H.
Rachel Reetzke, Ph.D., CCC-SLP
Abraham Reichenberg, Ph.D.
Debra L. Reisinger, Ph.D.
Ann Reynolds, M.D.
Sally J. Rogers, Ph.D.
Mustafa Sahin, M.D., Ph.D.
Alexandra C. Salem, M.S.
Lawrence Scahill, M.S.N., Ph.D.
Lauren M. Schmitt, Ph.D.
Andrea Schneider, Ph.D.
David J. Segal, Ph.D.
Rebecca Shalev, Ph.D.
Jill L. Silverman, Ph.D.
Lalitha Sivaswamy, M.D.
Janice Smith, Ph.D.
Siddharth Srivastava, M.D.
Theresa V. Strong, Ph.D.
Katherine Sullivan, Ph.D.
Bonnie P. Taylor, Ph.D.
Robyn P. Thom, M.D.
Angela John Thurman, Ph.D.
Christina Kang Toolan, Ph.D.
Maksim Tsvetovat, Ph.D.
Tychele N. Turner, Ph.D.
Judy Van de Water, Ph.D.
Fred R. Volkmar, M.D.
Paul P. Wang, M.D.
Felicia Widjaja, M.P.H.
Serena Wieder, Ph.D.
Thomas Wiese, M.D.
Hayes Wong, Ph.D.
Katharine E. Zuckerman, M.D., M.P.H.
About the Authors
Eric Hollander, M.D., is the Director of the Autism and Obsessive Compulsive Spectrum Program at the Psychiatric Research Institute of Montefiore Einstein and Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine, in Bronx, New York.
Randi Hagerman, M.D., is the Endowed Chair in Fragile X Research for the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute and Distinguished Professor of Pediatrics in the Department of Pediatrics at the University of California, Davis Medical Center in Sacramento, California.
Casara Ferretti, M.S., M.A., is a Predoctoral Research Associate in the Autism and Obsessive Compulsive Spectrum Program at the Psychiatric Research Institute of Montefiore Einstein and Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine, in Bronx, New York. She is a PhD candidate in the Clinical Psychology PhD program with Health Emphasis at Ferkauf Graduate School of Psychology, Yeshiva University.
Carousel Control - items will scroll by tabbing through them, otherwise arrows can be used to scroll one item at a time